Alaunos Therapeutics (TCRT) Change in Accured Expenses (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Change in Accured Expenses came in at -$5000.0 in Q1 2026, down 109.09% YoY from $55000.0 in Q1 2025, and down 104.1% on a QoQ basis from $122000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Change in Accured Expenses (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 18 years of Change in Accured Expenses data on file, last reported at -$5000.0 in Q1 2026.
- Quarterly Change in Accured Expenses fell 109.09% year-over-year to -$5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36000.0 (up 91.26% YoY) and the FY2025 annual result came in at $24000.0, up 102.06% from the prior year.
- Change in Accured Expenses slipped to -$5000.0 in Q1 2026, from $122000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $1.9 million in Q3 2022 to a low of -$2.2 million in Q4 2022.
- A 5-year average of -$341294.1 and a median of -$174000.0 in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses plunged 523.36% — and 2025, when it jumped 163.54%.
- Tracing TCRT's Change in Accured Expenses over 5 years: stood at -$2.2 million in 2022, then increased by 21.07% to -$1.7 million in 2023, then soared by 88.91% to -$192000.0 in 2024, then soared by 163.54% to $122000.0 in 2025, then sank by 104.1% to -$5000.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$5000.0 (Q1 2026), $122000.0 (Q4 2025), and -$188000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | -63,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,000.00 |
| Mar 31, 2026 | -5,000.00 |
| Dec 31, 2025 | 122,000.00 |
| Dec 31, 2025 | 122,000.00 |
| Sep 30, 2025 | -188,000.00 |
| Sep 30, 2025 | -188,000.00 |
| Jun 30, 2025 | 35,000.00 |
| Jun 30, 2025 | 35,000.00 |
| Mar 31, 2025 | 55,000.00 |
| Mar 31, 2025 | 55,000.00 |
| Dec 31, 2024 | -192,000.00 |
| Dec 31, 2024 | -192,000.00 |
| Sep 30, 2024 | -174,000.00 |
| Sep 30, 2024 | -174,000.00 |
| Jun 30, 2024 | -101,000.00 |
| Jun 30, 2024 | -101,000.00 |
| Mar 31, 2024 | -697,000.00 |
| Mar 31, 2024 | -697,000.00 |
| Dec 31, 2023 | -1.73 Mn |
| Dec 31, 2023 | -1.73 Mn |